Gyre Therapeutics Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in th… Read more
Gyre Therapeutics Inc. - Asset Resilience Ratio
Gyre Therapeutics Inc. (GYRE) has an Asset Resilience Ratio of 12.33% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2024)
This chart shows how Gyre Therapeutics Inc.'s Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Gyre Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $19.65 Million | 12.33% |
| Total Liquid Assets | $19.65 Million | 12.33% |
Asset Resilience Insights
- Moderate Liquidity: Gyre Therapeutics Inc. has 12.33% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Gyre Therapeutics Inc. Industry Peers by Asset Resilience Ratio
Compare Gyre Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Gyre Therapeutics Inc. (2006–2024)
The table below shows the annual Asset Resilience Ratio data for Gyre Therapeutics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.85% | $14.86 Million | $125.41 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $116.54 Million | -- |
| 2022-12-31 | 12.50% | $10.60 Million | $84.75 Million | +8.00pp |
| 2021-12-31 | 4.50% | $2.50 Million | $55.66 Million | -47.16pp |
| 2020-12-31 | 51.66% | $48.99 Million | $94.85 Million | -10.74pp |
| 2019-12-31 | 62.40% | $61.50 Million | $98.55 Million | -8.78pp |
| 2018-12-31 | 71.18% | $88.91 Million | $124.92 Million | +25.70pp |
| 2017-12-31 | 45.48% | $17.97 Million | $39.51 Million | +27.63pp |
| 2016-12-31 | 17.85% | $6.80 Million | $38.09 Million | +12.96pp |
| 2015-12-31 | 4.89% | $3.40 Million | $69.52 Million | -40.60pp |
| 2014-12-31 | 45.50% | $50.95 Million | $112.00 Million | +19.55pp |
| 2013-12-31 | 25.94% | $37.84 Million | $145.87 Million | +3.41pp |
| 2012-12-31 | 22.53% | $42.72 Million | $189.58 Million | -11.45pp |
| 2011-12-31 | 33.98% | $87.72 Million | $258.13 Million | +15.65pp |
| 2010-12-31 | 18.33% | $48.17 Million | $262.79 Million | +9.83pp |
| 2009-12-31 | 8.50% | $27.16 Million | $319.38 Million | -29.20pp |
| 2008-12-31 | 37.71% | $37.16 Million | $98.55 Million | +3.72pp |
| 2007-12-31 | 33.99% | $33.64 Million | $98.96 Million | +18.69pp |
| 2006-12-31 | 15.29% | $12.45 Million | $81.37 Million | -- |